Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What is the Anticipated CAGR of the Hepatitis D Market, and What Factors Will Drive It?
The market size for hepatitis D has seen consistent growth in the past few years. Its growth is projected to increase from $0.72 billion in 2024 to $0.76 billion in 2025, with a compound annual growth rate (CAGR) of 4.6%. The historical growth of this market has been due to factors such as limited treatment choices, high occurrence in regions where the disease is endemic, co-infection with hepatitis B, low levels of awareness and diagnosis, as well as governmental vaccination initiatives.
The market size for hepatitis D is projected to expand consistently over the next several years, reaching $0.90 billion in 2029 with a 4.4% Compound Annual Growth Rate (CAGR). The predicted development over the forecast period is largely due to expanded coverage of reimbursement policies for new therapies, increased healthcare investments, policy changes favoring combined treatments, growth in hepatitis B vaccine uptake, and amplified public health initiatives. Several anticipated trends for the forecast period encompass progress in molecular diagnostic techniques, a move towards customised liver disease treatment, the exploration of new RNA-based therapies, extended clinical trials for hepatitis D solutions, and the adoption of telemedicine for managing hepatitis.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21202&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Hepatitis D Market?
The escalating incidence of hepatitis B is anticipated to drive the expansion of the hepatitis D market in the near future. Hepatitis B is a viral infection that impacts the liver, resulting in symptoms such as jaundice, fatigue, and abdominal discomfort, and can develop into chronic liver conditions or liver cancer if not treated. The rise in hepatitis B infections is linked to unprotected intercourse, needle sharing, transmission from mother to child during birth, and inadequate immunization coverage in some areas. Hepatitis D depends on the Hepatitis B virus for its replication, utilizing the surface antigen of Hepatitis B to infect the liver cells, emphasizing the crucial role of dual infection of both viruses in the development of liver diseases. As an example, in November 2023, the Department of Health and Human Services, a US-based governmental department, reported that in 2022, cases of chronic hepatitis B had increased by 11% from 2021. Thus, the growing prevalence of hepatitis B is fueling the expansion of the hepatitis D market.
Which Key Market Segments Comprise the Hepatitis D Market and Drive Its Revenue Growth?
The hepatitis d market covered in this report is segmented –
1) By Type: Acute, Chronic
2) By Diagnosis: Blood Tests, Elastography, Liver Biopsy, Serologic Testing, Other Diagnosis
3) By Distribution Channel: Hospital pharmacies, Retail pharmacies, Online Pharmacies
4) By End-Users: Clinic, Hospital, Other End Users
Subsegments:
1) By Acute: Self-limiting Acute Hepatitis D, Severe Acute Hepatitis D
2) By Chronic: Compensated Chronic Hepatitis D, Decompensated Chronic Hepatitis D
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21202&type=smp
Which Areas Are Leading Regions in the Hepatitis D Market Expansion Across the Globe?
North America was the largest region in the hepatitis D market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis d market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Strategic Trends Steering theHepatitis D Market Direction?
Prominent corporations in the hepatitis D market are striving to introduce novel formulations such as recombinant vaccines to improve immunity efficacy and provide prolonged defense against the virus. Recombinant vaccines are those created by implanting a gene encoding a viral protein into a host organism, like bacteria or yeast, to produce the protein. This protein is subsequently used to prompt an immune response without triggering the disease. For example, in December 2022, VBI Vaccines Inc., a biotech firm from the United States, obtained approval from Health Canada for PreHevbrio [3-antigen Hepatitis B Vaccine (Recombinant)], an adult vaccine for active immunization against all known subtypes of hepatitis B aged 18 and over. The authorization also covers prevention of hepatitis D, as it stems from the delta agent, that cannot occur without a hepatitis B infection. The approval stems from positive outcomes from two crucial Phase 3 clinical trials, protect and constant, which showed higher seroprotection rates with PreHevbrio compared to the single-antigen engerix-B vaccine.
View the full report here:
https://www.thebusinessresearchcompany.com/report/hepatitis-d-global-market-report
How Is the Hepatitis D Market Conceptually Defined?
Hepatitis D, also known as hepatitis delta, is a liver infection caused by the hepatitis D virus (HDV). It is considered the most severe form of viral hepatitis and occurs only in individuals who are already infected with the hepatitis B virus (HBV). Hepatitis D virus depends on hepatitis B virus for its replication and survival, making it a co-infection or superinfection.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21202
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model